GTCM
APLS

Gyon Technologies Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Gyon Technologies Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-110
Closed -$5.69K – 41
2022
Q4 		$5.69K Buy
+110
New +$5.83K ﹤0.01% 451

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gyon Technologies Capital Management's APLS Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 110 shares — an estimated $5.69K sold.

Gyon Technologies Capital Management first reported a position in APLS in Q4 2022 and held it in 1 quarter. The position peaked at $5.69K in Q4 2022. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 110 Apellis Pharmaceuticals shares in Q1 2023, an estimated $5.69K.
  • Gyon Technologies Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Apellis Pharmaceuticals position peaked at $5.69K in Q4 2022.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.